However their effect on development of esophageal adenocarcinoma is less clear.
Dr Thomas Vaughan and colleagues from Seattle assessed the role of NSAID in developing esophageal adenocarcinoma in Barrett's esophagus.
The researchers also assessed the development of precursor lesions, a metaplastic disorder that confers a high risk of esophageal adenocarcinoma.
The research team conducted a prospective study of the relation between duration, frequency, and recency of NSAID use and esophageal adenocarcinoma risk.
The relation between NSAID use and aneuploidy, or tetraploidy was also investigated.
A cohort of 350 people with Barrett's esophagus was included for a median follow-up of 66 months.
The team used proportional-hazards regression to calculate hazard ratios adjusted for age, sex, cigarette use, and anthropometric measurements.
Compared with never users, the hazard ratio for esophageal adenocarcinoma in current NSAID users was 0.3.
|5-year incidence of esophageal adenocarcinoma was 7% for users vs 14% for never users|
The researchers found that in former users was the hazard ratio was 0.7.
The team noted that the 5-year cumulative incidence of esophageal adenocarcinoma was 14% for never users, and 10% for former users.
For current NSAID users, the 5-year incidence of esophageal adenocarcinoma was 7%.
When the team took changes in NSAID use during follow up into account, the associations were strengthened.
The hazard ratio for esophageal adenocarcinoma for current users at baseline or afterwards was 0.2 compared with never users.
Compared with never users, the researchers found that current NSAID users had less aneuploidy and tetraploidy.
Dr Vaughan's team concluded, “NSAID use might be an effective chemopreventive strategy, reducing the risk of neoplastic progression in Barrett's esophagus.”